ANKRD17: A Potential Drug Target and Biomarker for Serologically Defined Breast Cancer

Target Name: ANKRD17

NCBI ID: G26057

ANKRD17: A Potential Drug Target and Biomarker for Serologically Defined Breast Cancer

Breast cancer is a leading cause of cancer-related deaths in women, with over 280,000 new cases per year in the United States alone. Despite advances in treatment, the survival rate for breast cancer remains poor, with a five-year survival rate of only 23%. Therefore, there is a need for new and effective treatments to improve outcomes for breast cancer patients.

One potential drug target for breast cancer is ANKRD17, a serologically defined breast cancer antigen (SDBA) that was identified by researchers at the University of California, San Diego School of Medicine. ANKRD17 is a protein that is expressed in the majority of breast cancer cells and has been shown to be associated with the development and progression of breast cancer.

In recent years, researchers have been investigating the potential clinical applications of ANKRD17 as a drug target. One of the main reasons for this is the high level of ANKRD17 expression in breast cancer cells, which makes it a promising target for cancer treatments. Additionally, ANKRD17 has been shown to be involved in several important processes that are involved in the development and progression of breast cancer, such as cell signaling, angiogenesis, and immune evasion.

In addition to its potential as a drug target, ANKRD17 has also been identified as a potential biomarker for breast cancer. Tumor expression of ANKRD17 has been shown to be associated with the poor prognosis of breast cancer patients, and high ANKRD17 expression has been shown to be associated with the development of metastasis. Therefore, ANKRD17 has the potential to serve as a biomarker for breast cancer, allowing for earlier detection and more effective treatment.

The identification of ANKRD17 as a potential drug target and biomarker for breast cancer makes it an important area of 鈥嬧?媟esearch for cancer researchers. Further studies are needed to determine the full potential of ANKRD17 as a drug and biomarker for breast cancer. But also highlight the potential of ANKRD17 as a new target for breast cancer treatment and the importance of continued research in this field.

Protein Name: Ankyrin Repeat Domain 17

Functions: Could play pivotal roles in cell cycle and DNA regulation (PubMed:19150984). Involved in innate immune defense against viruse by positively regulating the viral dsRNA receptors DDX58 and IFIH1 signaling pathways (PubMed:22328336). Involves in NOD2- and NOD1-mediated responses to bacteria suggesting a role in innate antibacterial immune pathways too (PubMed:23711367). Target of enterovirus 71 which is the major etiological agent of HFMD (hand, foot and mouth disease) (PubMed:17276651). Could play a central role for the formation and/or maintenance of the blood vessels of the circulation system (By similarity)

More Common Targets